CareFusion 303, Inc.
Case
•
[2021] APO 11
•26 February 2021
Details
AGLC
Case
Decision Date
CareFusion 303, Inc. [2021] APO 11
[2021] APO 11
26 February 2021
CaseChat Overview and Summary
CareFusion 303, Inc. faced an objection from the examiner regarding the manner of manufacture of their patent application. The dispute centered on whether the invention was a scheme rather than a method of manufacture. The case was decided by Dr. S.D. Barker, the Deputy Commissioner of Patents. The primary legal issue was to determine whether the invention claimed in the patent was a scheme or a manner of manufacture. The court examined the balance of considerations, including whether the invention achieved a practical and useful result. The reasoning involved an assessment of whether the claims were limited to situations where the practical and useful result was assured, and whether the ingenuity lay in the implementation of the process on a system or in the scheme itself.
Dr. Barker concluded that the contribution to the invention was a scheme rather than a manner of manufacture. The reasoning was based on the fact that the weight given to the practical and useful result was not sufficient to disturb the balance of considerations. The court noted that while the invention used generic computing technology to execute a scheme, the result achieved in the pharmaceutical field was more than mere serendipity. However, the claims were not limited to situations where this advantage was assured. The court found that the ingenuity lay in the way the list of orders was ordered rather than the implementation, as there was no evidence of ingenuity in implementing the process on a system or preparing the system. The potential for a practical and useful result was acknowledged, but the result was not guaranteed, leading to minimal weight being given to this consideration.
The outcome was that the Deputy Commissioner allowed the applicant the opportunity to propose amendments to the claims to more strongly link them to the practical and useful result. This decision provided a pathway for the applicant to potentially overcome the examiner's objection by refining the claims to better align with the patentable subject matter requirements.
Dr. Barker concluded that the contribution to the invention was a scheme rather than a manner of manufacture. The reasoning was based on the fact that the weight given to the practical and useful result was not sufficient to disturb the balance of considerations. The court noted that while the invention used generic computing technology to execute a scheme, the result achieved in the pharmaceutical field was more than mere serendipity. However, the claims were not limited to situations where this advantage was assured. The court found that the ingenuity lay in the way the list of orders was ordered rather than the implementation, as there was no evidence of ingenuity in implementing the process on a system or preparing the system. The potential for a practical and useful result was acknowledged, but the result was not guaranteed, leading to minimal weight being given to this consideration.
The outcome was that the Deputy Commissioner allowed the applicant the opportunity to propose amendments to the claims to more strongly link them to the practical and useful result. This decision provided a pathway for the applicant to potentially overcome the examiner's objection by refining the claims to better align with the patentable subject matter requirements.
Details
Key Legal Topics
Areas of Law
-
Intellectual Property Law
Legal Concepts
-
Patents
-
Scheme
-
Ingenuity
-
Contribution to Idea
Actions
Download as PDF
Download as Word Document
Citations
CareFusion 303, Inc. [2021] APO 11
Most Recent Citation
CareFusion 303, Inc. [2023] APO 17
Cases Citing This Decision
10
CareFusion 303, Inc.
[2023] APO 17
BaVelPay S.L.U (B-67506527)
[2022] APO 78
Venkat Thandra; Ahmed Farouk Shaaban
[2022] APO 65
Cases Cited
13
Statutory Material Cited
0
D'Arcy v Myriad Genetics Inc
[2015] HCA 35
Commissioner of Patents v RPL Central Pty Ltd
[2015] FCAFC 177
Aristocrat Technologies Australia Pty Limited
[2016] APO 49